This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.
Non-vitamin K oral anticoagulant options for patients with non-valvular atrial fibrillation and renal impairment
This NOAC dosing guide has been commissioned by Bayer, who also provided funding for its development. Bayer reviewed and approved the scope and pre-meeting documents, suggested the Chair and experts for the group, and put the dosing guide through full medical approval to ensure its compliance with appropriate regulations.
This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.